Understanding how certain proteins can trigger cell death in cancer cells
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
This study is looking at how certain proteins in our cells can help kill cancer cells, with the goal of finding better treatments that could help patients live longer and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11078744 on NIH RePORTER |
What this research studies
This research investigates the role of BAX and BAK proteins in inducing cell death in cancer cells, which is crucial for developing new cancer therapies. By focusing on how these proteins interact with other molecules in the cell, the research aims to find ways to enhance the effectiveness of existing cancer treatments. Patients may benefit from new therapeutic strategies that could lead to improved outcomes and longer-lasting responses to treatment. The study employs advanced techniques to analyze these protein interactions and their effects on cancer cell survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are resistant to current therapies or those who have not responded well to existing treatments.
Not a fit: Patients with early-stage cancers that are easily treatable with standard therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new cancer treatments that improve patient survival rates and treatment responses.
How similar studies have performed: Previous research has shown promising results in targeting BCL-2 family proteins for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Cheng, Emily H — Sloan-Kettering Inst Can Research
- Study coordinator: Cheng, Emily H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.